Second-quarter earnings results from two of the Big Three – Teva and Mylan – hold much of the intrigue in August, while more competition in the nascent Avastin biosimilar market could materialize in Europe.

Sawai has followed-up on a raft of approvals announced earlier this year with launch plans, including for the first generics of Daiichi Sankyo’s Memary (memantine hydrochloride) Alzheimer’s disease treatment in three presentations.

Sales growth through new product launches and increasing the value of its current portfolio will allow Sawai to increase sales by around a tenth this year, the Japanese firm has forecasted, as it also revealed full-year financials for the 12 months ended 31 March 2020.

Sawai has received a raft of generics approvals from Japan’s Ministry of Health, Labour and Welfare, including approval for a tadalafil rival to Cialis and 10 first-time generic approvals.